Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 3, 1998, Pages 302-311

  Grossmann, Matthias ^a,b   Dobrev, Dobromir ^a   Kirch, Wilhelm ^a  

^a Univ of Technology

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; BENZYL ALCOHOL; GLIBENCLAMIDE; LIDOCAINE; N(G) METHYLARGININE; NIFEDIPINE; NITRIC OXIDE; PHENYLEPHRINE; POLYSORBATE 80; POTASSIUM CHANNEL; PROPRANOLOL; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2 ALPHA TROMETAMOL; PROSTAGLANDIN SYNTHASE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HAND; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN COMPLIANCE;

ADULT; AMIODARONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HAND; HUMANS; MALE; REFERENCE VALUES; VASODILATION; VASODILATOR AGENTS; VEINS;

EID: 0031691030     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90179-5     Document Type: Article

References (44)

1. Mason JW. Drug therapy: amiodarone. N Engl J Med 1987;316:455-66.
2. Follmer C, Aomine M, Yeh J, Singer D. Amiodarone-induced block of sodium current in isolated cardiac cells. J Pharmacol Exp Ther 1987;243:187-94.
3. Lubic SP, Nguyen KPV, Dave B, Giacomini JC. Antiarrhythmic agent amiodarone possesses calcium channel blocker properties. J Cardiovasc Pharmacol 1994;24:707-14.
4. Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992;43:69-110.
5. Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with β-adrenoceptor and adenylate cyclase in rat. Br J Pharmacol 1995;116:1949-56.
6. Du XJ, Esler MD, Dart AM. Sympatholytic action of intravenous amiodarone in the rat heart. Circulation 1995;91:462-70.
7. Chalier R, Deltour G, Baudine A, Challet F. Pharmacology of amiodarone, an antiarrhythmic drug with a new biological profile. Drug Res 1968;18:1408-17.
8. Kosinski EJ, Albin JB, Young E, Lewis SM, Leland OS. Hemodynamic effects of intravenous amiodarone. J Am Coll Cardiol 1984;4:565-70.
9. Aomine M, Singer DH. Negative inotropic effects of amiodarone on isolated guinea pig papillary muscle. Cardiovasc Res 1990;24:182-90.
10. 2+ associated with cellular injury to human pulmonary artery endothelial cells. Toxicol Appl Pharmacol 1990;103:156-64.
11. Hagelüken A, Nürnberg B, Harhammer R, Grünbaum L, Schunack W, Seifert R. The class III antiarrhythmic drug amiodarone directly activates pertussis toxin-sensitive G proteins. Mol Pharmacol 1995;47:234-40.
12. Förstermann U, Pollock JS, Schmidt HHHW, Heller M, Murad F. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fraction of bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88:1788-92.
13. 2+-dependent and -independent pathways. Biochem J 1991;280(pt 2):281-7.
14. Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997;127:294-303.
15. Gough WB, Zeiler RH, Barreca P, El-Sherif N. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J Cardiovasc Pharmacol 1982;4: 375-80.
16. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins: 1. Br J Clin Pharmacol 1994;38:181-96.
17. Grossmann M, Abiose A, Tangphao O, Blaschke TF, Hoffman BB. Morphine induced venodilation in humans. Clin Pharmacol Ther 1996;60:554-60.
18. Pan H, Hoffman BB, Pershe RA, Blaschke TF. Decline in beta adrenergic receptor-mediated relaxation with aging in man. J Pharmacol Exp Ther 1986;239:802-7.
19. Bowman AJ, Chen CPLH, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994;38:199-204.
20. Strobel WM, Lüscher TF, Simper D, Linder L, Haefeli WE. Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action. Clin Pharmacol Ther 1996;60:435-43.
21. Haefeli WE, Gumbleton M, Benet LZ, Hoffman BB, Blaschke TF. Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human hand veins. Clin Pharmacol Ther 1992;52:590-6.
22. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981;6:429-53.
23. Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP. Histamine-releasing properties of polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions 1985;16:470-7.
24. 2α-receptors in the canine mesenteric bed. Prostaglandins 1979;18:221-33.
25. O'Grady J, Oh V, Turner P. Effects of propranolol and oxprenolol on the vasoconstrictor response to noradrenaline in the superficial hand vein in man. Eur J Clin Pharmacol 1978;14:83-5.
26. White CB, Udwadia BP. α-Adrenoceptors in the human dorsal hand vein, and the effects of propranolol and practolol on venous sensitivity to noradrenaline. Br J Clin Pharmacol 1975;2:99-105.
27. Robinson BF, Dobbs RJ, Kelsey CR. Effects of nifedipine on resistance vessels, arteries and veins in man. Br J Clin Pharmacol 1980;10:433-8.
28. Arner M, Hogestatt ED. Actions of some vasodilators on isolated human hand veins. Acta Physiol Scand 1987;130:671-7.
29. Gherardini G, Evans GR, Milner SM, Gurlek A, Palmer B, Gazelius B, et al. Comparison of vascular effects of calcitonin gene-related peptide and lidocaine on human veins. J Reconstr Microsurg 1996;12:241-4.
30. Pitman MR, Karlsson JOG, Griffith TM. Ionic mechanisms contributing to the vasorelaxant properties of iodinated contrast media: a comparison of iohexal and iodixanol in the rabbit isolated aorta. Br J Pharmacol 1996;119:685-90.
31. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
32. Moncada S, Herman AG, Higgs EA. Differential formation of prostacyclin by layers of the arterial wall: an explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 1977;11:323-44.
33. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;299:373-6.
34. Chen G, Cheung DW. Characterization of acetylcholine-induced membrane hyperpolarization in endothelial cells. Circ Res 1992;70:257-63.
35. 2 and cyclooxygenase-2. Eur J Biochem 1994;226:125-31.
36. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor-1β by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation 1997;96:1386-9.
37. Mombouli JV, Vanhoutte PM. Endothelium-derived hyperpolarizing factor(s): updating the unknown. Trends Pharmacol Sci 1997;18:252-6.
38. 2α on superficial hand veins of man. Br J Pharmacol 1972;44:374P-5P.
39. Kukovetz WR, Holzmann S, Wurm A, Poch G. Prostacyclin increases cAMP in coronary arteries. J Cyclic Nucleotide Res 1979;5:469-76.
40. Nakashima M, Vanhoutte PM. Isoproterenol causes hyperpolarization through opening of ATP-sensitive potassium channels in vascular smooth muscle of the canine saphenous vein. J Pharmacol Exp Ther 1995;272:379-84.
41. Noma A, Shibaski T. Membrane current through adenosine-triphosphate regulated potassium channels in guinea pig ventricular cells. J Physiol 1985;363:463-80.
42. Stäubli M, Bircher J, Galeazzi RL, Remund H, Studer H. Serum concentrations of amiodarone during long term therapy: relation to dose, efficacy and toxicity. Eur J Clin Pharmacol 1983;24:485-94.
43. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984;9:136-56.
44. Watt AH, Hutchings A, Stephens MR, Routledge PA. Plasma amiodarone concentrations during intravenous infusion. Br J Clin Pharmacol 1986;21:525-8.